ClinicalTrials.gg
CompletedNCT04925674Updated May 15, 2025

Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.

A Phase 1 interventional study of HEC53856 in Hemodialysis and Peritoneal Dialysis, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 7 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HEC53856 capsules on anemia in subjects with chronic kidney disease on dialysis.

Read the detailed description

The purpose of this multicenter, open-label, dose-increasing, multiple-dose study was to evaluate the safety, tolerability,PK and preliminary efficacy of HEC53856 capsules in renal anemia subjects on dialysis.

The study consists of two parts, hemodialysis or peritoneal dialysis . Within each part participants will be administrated for HEC53856.

There are three study periods:

Screening period :up to 2weeks; Treatment period: 6 weeks(except that 7 weeks in the 100mg cohort in the hemodialysis); Follow-up period: 2weeks.

02

Conditions studied

  • Hemodialysis
  • Peritoneal Dialysis
03

In context

Lead sponsor

Sunshine Lake Pharma Co., Ltd. is the lead sponsor of 83 studies on the registry; 13 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject voluntarily participated in this clinical trial and signed an form;
  2. 18-70 years old, weight 45\~90kg, including cut-off value;
  3. Hemodialysis (Hemodialysis, HD): Patients with end-stage renal disease who are on stable dialysis receive 3 times a week hemodialysis for at least 3 months before screening, and can receive 3 times a week hemodialysis at regular intervals during the test. The duration of the subject's hemodialysis treatment must be 3-4.5 hours (including the cut-off value); Peritoneal dialysis: For patients with end-stage renal disease on stable dialysis, the subject must receive peritoneal dialysis for at least 3 months before screening;
  4. Subjects stop EPO 14 days or 5 half-lives (whichever is the longest) before taking the test drug for the first time;
  5. Subjects have stable dialysis methods and dialysis prescriptions, and are expected to have no major treatment changes or no drastic changes in their condition during the clinical trial period;
  6. During the screening period, the value obtained by the two tests of Visit 1 and Visit 2 must be > or = 8.0 g/dL and \<11.0 g/dL, and the difference between the two must be \< or = 1.5 g/dL.

Exclusion criteria

Exclusion Criteria:

  1. Existence of past medical history or conditions that may cause anemia other than nephropathy, including but not limited to blood system diseases, such as thalassemia, aplastic anemia, hemolytic anemia, multiple myeloma, myelodysplastic syndrome, etc.; diseases that may affect red blood cell production, such as systemic lupus erythematosus, rheumatoid arthritis, etc.; Bleeding diseases, such as gastrointestinal bleeding, obstetrics and gynecology bleeding diseases, etc.
  2. During the study period, those who plan to change the dialysis method/mode or the flux of the hemodialysis machine, such as changing from peritoneal dialysis to hemodialysis
  3. Those who have any of the following heart/cerebrovascular diseases:

    1. Acute coronary syndrome, stroke (except lacunar infarction) or thromboembolic disease (such as deep vein thrombosis or pulmonary embolism) occurred within 6 months before screening;
    2. Heart Function III of New York Society of Cardiology Or grade IV congestive heart failure, or severe arrhythmia, including but not limited to ventricular tachycardia, ventricular fibrillation, III degree atrioventricular block, etc.
  4. Those who have any of the following medical or surgical history:

    1. Those who plan to undergo major surgery 3 months before screening or during the study period (except for hemodialysis access repair) or blood transfusion therapy;
    2. Have peritoneal dialysis related 3 months before screening Peritonitis, history of infection or leakage of peritoneal tube tunnel;
    3. history of malignant tumor within 5 years prior to screening (except for cured skin basal cell carcinoma and cervical carcinoma in situ), or current assessment of potential malignant tumor;
    4. suffering Uncontrollable or symptomatic secondary hyperparathyroidism, plasma iPTH>800pg/ml;
    5. History of dysphagia or any gastrointestinal disease that affects drug absorption, history of gastric/jejunum/colon resection; f ) Those who have a serious infection and are receiving systemic antibiotic treatment;

    g) Anyone who has participated or plans to participate in an organ transplant within 6 months; h) Have a history of chronic liver disease (such as: chronic infectious hepatitis, chronic autoimmune liver disease, cirrhosis Or liver fibrosis); i) Patients with a history of polycystic kidney disease.

  5. Any of the following laboratory abnormalities during the screening period:

    1. Folic acid \<6.8nmol/L (3ng/ml) and/or VitB12\<74pmol/L (100ng/ml);
    2. Serum albumin \<3 g/dL;
    3. AIDS antibody , Treponema pallidum antibody, surface antigen or antibody positive for any one;
    4. >3× and/or AST>3×ULN, or total >1.5× ULN;
  6. Subjects received intravenous iron supplementation within 4 weeks before screening, or used Chinese patent medicines, androgens and anabolic hormone drugs, hypoxia-inducible factor prolyl hydroxylase for the treatment of anemia within 4 weeks before screening Inhibitors (such as Roxastat capsules) and other drugs (except ESAs and their derivatives, oral irons, stable oral irons can be taken within 4 weeks before the screening, and in the screening period and after the start of the trial drug Continue to take the fixed dose for 6 weeks.)
  7. Subjects who are expected to take BCRP inhibitors, BCRP inducers, CYP2C8 inhibitors and inducers within 14 days before taking the test drug (or 5 half-lives of the drug, whichever is the longest) until the end of the drug;
  8. Those who have a history of drug abuse or drug abuse within 6 months before screening;
  9. The mean systolic blood pressure =180 mmHg and/or the diastolic blood pressure > or = 110 mmHg of two supine blood pressure measurements at least 1 hour apart during the screening period;
  10. People with a history of severe allergic disease or drug allergy, or those who are allergic to test drugs or their ;
  11. Those who drink more than 14 units per week in the 3 months before screening (1 unit of alcohol ˜ 360 mL of beer or 45 mL of spirits with 40% alcohol content or 150 mL of wine), or those who cannot abstain from alcohol during the hospitalization;
  12. Those who smoked more than 10 cigarettes per day in the 3 months before screening, or who could not stop using any tobacco products during the hospitalization;
  13. Women who have a positive pregnancy test or are breastfeeding, or men and women who refuse to take effective measures within 4 weeks from the signing of the form to the end of the last trial drug administration;
  14. Participated in other clinical trials within 3 months before screening (Definition of participation: accepted experimental drugs or instrument);
  15. Subjects may not be able to complete all research visits or procedures required by the research protocol, and/or fail to comply with all required research procedures;
  16. The investigator believes that there are other factors that are not suitable for participating in this trial;
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    HEC53856

    HEC53856 Oral TIW There will be a total of 3 dose cohorts in the hemodialysis: 100mg,150mg,200mg; There will be only one dose cohort in the peritoneal dialysisp:100mg.

    Drug: HEC53856

Interventions

  • The 100mg dose cohort in the hemodialysis: D1 single oral administration of the investigation product 2.5h before hemodialysis; Three times a week for 6 weeks starting from D8, oral administration of the test drug 2.5h after hemodialysis. The rest dose cohorts in the hemodialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product 2.5h after hemodialysis. The dose cohort in the peritoneal dialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product after fasting.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    To assess the safety and tolerability of therapy by incidence of treatment-emergent adverse events after multiple doses of HEC53856 capsule

    Time frame: Up to 2 weeks after last dose

Secondary outcomes

  1. AUC0-t

    Area under the concentration versus time curve (AUC) from time zero to the time of the last quantifiable concentration

    Time frame: Up to 72 hours after single and multiple drug dosing

  2. Cmax

    Maximum observed plasma concentration

    Time frame: Up to 72 hours after single and multiple drug dosing

  3. Tmax

    Time of the maximum observed plasma concentration

    Time frame: Up to 72 hours after single and multiple drug dosing

  4. T½

    Apparent terminal elimination half-life

    Time frame: Up to 72 hours after single and multiple drug dosing

  5. Vz/F

    Apparent volume of distribution

    Time frame: Up to 72 hours after single and multiple drug dosing

  6. Changes in mean hemoglobin

    Changes in mean hemoglobin (Hb) relative to baseline during visit 8 and 9.

    Time frame: Up to 2 weeks after the last dose

  7. Hemoglobin response

    Percentage of subjects who met the hemoglobin response after dosing

    Time frame: Up to 2 weeks after the last dose

  8. E-AUC0-t

    Area under the EPO concentration versus time curve (AUC) from time zero to the time of the last quantifiable concentration

    Time frame: Up to 72 hours after single and multiple drug dosing

  9. Emax

    Maximum observed EPO concentration

    Time frame: Up to 72 hours after single and multiple drug dosing

  10. E-Tmax

    Time of the maximum observed EPO concentration

    Time frame: Up to 72 hours after single and multiple drug dosing

  11. Serum lipid

    Changes in Serum lipid relative to baseline at visit 8.

    Time frame: week 6

  12. Indicators of iron

    Changes in the Indicators of iron relative to baseline at visit 8

    Time frame: week 6

  13. High-sensitivity C-reactive protein

    Changes in the High-sensitivity C-reactive protein relative to baseline at visit 8.

    Time frame: week 6

  14. Reticulocytes

    Changes in the mean Reticulocytes relative to baseline after doses.

    Time frame: Up to week 8

  15. VEGF

    Changes in the VEGF relative to baseline after doses.

    Time frame: week 6

07

Study locations

7 sites
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
  • Sichuan Provincial People's Hospital
    Chengdu, China
  • The First Affiliated Hospital of Shantou University Medical College
    Shantou, China
  • The First Hospital of China Medical University
    Shenyang, China
  • General Hospital of Tianjin Medical University
    Tianjin, China
  • Affiliated Hospital of Guangdong Medical University
    Zhanjiang, China
  • The Fifth Affiliated Hospital Sun Yat-sen University
    Zhuhai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Oct 2022, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2021
First posted
Jun 14, 2021
StartActual
Sep 10, 2021
Primary completionActual
Oct 19, 2022
CompletionActual
Oct 19, 2022
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04925674
Collaborators
Nicoya Therapeutics (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Jun 14, 2021
Start date
Sep 10, 2021
Primary completion
Oct 19, 2022
Completion
Oct 19, 2022
Last update
May 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HEC53856

Start the discussion